Nike hit with downgrade, Blue Apron cutting jobs, Gilead new cancer drug gets FDA approval

Here’s a look at some of the stocks the Yahoo Finance team will be watching for you today.

Verizon (VZ) shares were sharply higher after beating on both its top and bottom lines for last quarter. The wireless carrier added 66,000 Fios internet subscribers but lost video subscribers, which it says reflects the shift from traditional linear video to internet streaming. Verizon is the parent company of Yahoo Finance.

American Express (AXP) was lower Thursday morning. CEO Ken Chenault is leaving after 17 years at the helm. Stephen Squeri will take his spot. The credit card company also posted better-than-expected earnings after yesterday’s closing bell and raised it’s outlook for the coming year.

Nike (NKE) is also in the spotlight after Goldman Sachs lowered shares of the athletic apparel and sneaker maker to neutral from buy. The firm says it expects Nike stock to trade in a range while it works through excess inventory in the U.S. The downgrade comes ahead of their meeting with investors next week.

Blue Apron (APRN) is laying off 6% of its workforce or about 300 employees. The meal kit service company is trying to regain its footing after a tough time on the public market. The stock is down about 40% since going public in June.

Gilead Sciences (GILD) is moving higher in early trading. The FDA approved its new lymphoma therapy that helps the immune system identify and attack cancer cells. The drug is priced at $373,000. That’s about $100,000 less than similar class drug by Novartis (NVS).